NASDAQ: TMCITreace Medical Concepts Inc Stock
$7.05+0.15 (+2.17%)
Updated Apr 29, 2025
TMCI Price
$7.05
Fair Value Price
N/A
Market Cap
$441.46M
52 Week Low
$3.92
52 Week High
$11.33
P/E
-7.83x
P/B
3.91x
P/S
2.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$209.36M
Earnings
-$55.74M
Gross Margin
80.4%
Operating Margin
-24.12%
Profit Margin
-26.6%
Debt to Equity
0.92
Operating Cash Flow
-$37M
Beta
1.26
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TMCI Overview
Treace Medical Concepts Incorporated manufactures and sells medical devices to foot and ankle surgeons in the U.S. Its Lapiplasty procedure allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides the Lapiplasty Mini-Incision precision system. Treace Medical Concepts was founded in 2013 and is headquartered in Ponte Vedra Beach, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TMCI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
TMCI
Ranked#50 of 107
Ranked#50 of 107
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.56 | A | |
| $22.55 | A | |
| $14.22 | A |
Be the first to know about important TMCI news, forecast changes, insider trades & much more!
TMCI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TMCI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMCI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMCI is good value based on its book value relative to its share price (3.91x), compared to the US Medical Devices industry average (3.95x)
P/B vs Industry Valuation
TMCI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TMCI due diligence checks available for Premium users.
Valuation
TMCI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.83x
Industry
37.36x
Market
29.19x
TMCI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.91x
Industry
3.95x
TMCI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMCI's financial health
Profit margin
Revenue
$68.7M
Net Income
-$501.0k
Profit Margin
-0.7%
TMCI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TMCI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$217.1M
Liabilities
$104.2M
Debt to equity
0.92
TMCI's short-term assets ($161.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMCI's short-term assets ($161.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMCI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TMCI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
$3.4M
Financing
$26.0k
TMCI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TMCI vs Medical Device Stocks
Treace Medical Concepts Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.